Regenxbio (RGNX) Misses Q2 EPS by 44c

Regenxbio (NASDAQ: RGNX) reported Q2 EPS of ($1.38), $0.44 worse than the analyst estimate of ($0.94). Revenue for the quarter came in at $21.36 million versus the consensus estimate of $38.7 million.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.

You May Also Be Interested In

• Infleqtion raises Q2 revenue to $13.5M after contract restatement
• Yalla Group Limited (YALA) Reports Q2 EPS of $0.24
• PENN Entertainment (PENN) Reiterated at Market Outperform by Citizens as Relocation Announced